Search

everythinglearnresearchcommunity

for

Search:↓

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

64 drugs can cause hair loss, needing better monitoring and updated labels.

Scalp cooling helps prevent hair loss during chemotherapy, and minoxidil aids regrowth.

Cannabis, cryotherapy, and scalp cooling can help improve the quality of life for chemotherapy patients.

Insurance coverage for scalp cooling will make it more accessible to all chemotherapy patients.

Inhaling medicine may reduce side effects and improve treatment for a major lung cancer type.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

Promising cancer treatments were found, but the manufacturer closed.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

The drug combination was safe and showed promise in treating advanced tumors.

Provenge extends prostate cancer survival by about 4 months.

The treatment was effective and tolerable for advanced gastric cancer.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.